[组织型纤溶酶原激活剂与组织型纤溶酶原抑制剂在2型糖尿病中的作用]
[Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
作者信息
Rość D, Drewniak W, Kotschy M, Graczykowska-Koczorowska A, Raukuć D
机构信息
Katedry i Zakładu Patofizjologii, Bydgoszczy.
出版信息
Pol Merkur Lekarski. 1997 Jan;2(7):24-5.
The aim of study was the evaluation of tissue plasminogen activator (t-PA) and its inhibitor (PAI-1) in the II type diabetes on the base of the common fibrinolytic system tests as euglobulin lysis time (ELT) and the concentration of fibrin/fibrinogen products (FDP). The studies were performed in 21 outpatients suffering of II type diabetes aged 38-65 (median 56.0) years treated with diet and sulphonylcarbamide derivates. The control group contained 18 healthy persons aged 33-65 (median 42.0) years. In the blood the following determinations were performed: antigen of t-PA and PAI-1, ELT and FDP. In the blood of patients with II type diabetes increased. t-PA Ag and PAI-1 Ag concentrations were observed.
本研究旨在基于优球蛋白溶解时间（ELT）和纤维蛋白/纤维蛋白原降解产物（FDP）浓度等常见纤溶系统检测指标，评估Ⅱ型糖尿病患者体内组织型纤溶酶原激活物（t-PA）及其抑制剂（PAI-1）的情况。研究对象为21例年龄在38 - 65岁（中位数56.0岁）的Ⅱ型糖尿病门诊患者，这些患者接受饮食和磺酰脲类衍生物治疗。对照组包含18名年龄在33 - 65岁（中位数42.0岁）的健康人。检测了血液中的以下指标：t-PA和PAI-1抗原、ELT和FDP。观察到Ⅱ型糖尿病患者血液中t-PA抗原和PAI-1抗原浓度升高。
Zotero 插件